Cell and Gene Therapy Clinical Trials Market Size & Growth Forecast 2027–2036, By Segments (Phase, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cell and Gene Therapy Clinical Trials Market size was assessed at USD 14.2 billion in 2026 and is poised to grow at a 14.82% CAGR between 2027 and 2036, attaining USD 56.55 billion by 2036. The industry revenue for 2027 is estimated at USD 15.97 billion.
Get more details on this report
Request Free Sample ReportCell and Gene Therapy Clinical Trials Market Intelligence Snapshot
Regional Market Dynamics
- North America led with 53.45% share due to advanced clinical research infrastructure, strong biotech presence, and well-established trial execution and regulatory capabilities supporting complex therapy development.
- Asia Pacific is expanding at 16.58% CAGR due to rising clinical site capacity, improved research capabilities, and increased use of diverse patient populations for multicenter advanced therapy trials.
Segment Momentum
- Phase III held a 57.07% market share in 2026 because late-stage studies involve larger patient populations, multicenter execution, and extensive regulatory requirements, supported by mature oncology and rare disease pipelines.
- Cardiovascular Diseases is growing fastest as developers expand regenerative and gene-based therapies beyond oncology, targeting chronic conditions with significant unmet needs and increasing clinical development activity.
Market Expansion Drivers
- Advancements in CRISPR and vector delivery technologies accelerating development of targeted genetic therapies.
- Increasing regulatory support through accelerated approval pathways expanding clinical trial activity for advanced therapies.
- Rising biotech and pharmaceutical collaborations strengthening global multi-site cell and gene therapy trial infrastructure.
Leading Market Participants
- Prominent companies in the cell and gene therapy clinical trials market include IQVIA Holdings Inc. (United States), ICON plc (Ireland), Thermo Fisher Scientific Inc. (United States), Laboratory Corporation of America Holdings (United States), Charles River Laboratories International, Inc. (United States), Parexel International Corporation (United States), Syneos Health, Inc. (United States), Medpace Holdings, Inc. (United States), Novotech Health Holdings Pty Ltd. (Australia), Veristat, LLC (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 14.2 billion
- 2027 Estimated Market Size: USD 15.97 billion.
- Projected Market Size: USD 56.55 billion by 2036
- Growth Forecast: 14.82% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Phase III (Phase) | Oncology (Indication)
- Emerging Opportunity Segment: Phase I (Phase) | Cardiovascular Diseases (Indication)
Market Growth Drivers and Industry Trends
Advancements in CRISPR and vector delivery technologies accelerating development of targeted genetic therapies
Technological progress in genome editing and delivery mechanisms is reshaping the cell and gene therapy clinical trials market by enabling researchers to develop more targeted approaches for modifying or replacing disease-associated genetic material. Improvements in CRISPR-based editing can support greater precision in therapeutic development, while advances in vector technologies can improve the delivery of genetic payloads to intended cells. These developments broaden the range of conditions being investigated and strengthen clinical research activity around therapies designed to address underlying genetic mechanisms.
Increasing regulatory support through accelerated approval pathways expanding clinical trial activity for advanced therapies
More supportive regulatory frameworks and accelerated pathways for advanced therapies are encouraging the cell and gene therapy clinical trials market by reducing development barriers for potentially transformative treatments. Expedited regulatory mechanisms can facilitate closer interaction between developers and authorities, enabling promising therapies to progress through clinical development with greater clarity around evidence requirements and approval considerations. This environment encourages sponsors to advance innovative candidates into human studies while supporting continued investigation of therapies for conditions with significant unmet medical needs.
Rising biotech and pharmaceutical collaborations strengthening global multi-site cell and gene therapy trial infrastructure
Strategic collaboration between biotechnology companies and pharmaceutical organizations is expanding the resources available to the cell and gene therapy clinical trials market, particularly for complex multi-site studies. Partnerships can combine specialized scientific expertise, development capabilities, manufacturing resources, and clinical networks, allowing advanced therapies to move through trials more efficiently across different regions. Such collaboration also supports the establishment of coordinated trial infrastructure capable of handling specialized patient recruitment, treatment administration, monitoring, and data management requirements.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Advancements in CRISPR and vector delivery technologies accelerating development of targeted genetic therapies | 2.00% | High | North America, Europe | High | Near Term |
| Increasing regulatory support through accelerated approval pathways expanding clinical trial activity for advanced therapies | 1.70% | High | North America, Asia Pacific | High | Mid Term |
| Rising biotech and pharmaceutical collaborations strengthening global multi-site cell and gene therapy trial infrastructure | 1.30% | Moderate | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the cell and gene therapy clinical trials market, with a 53.45% share in 2026, reflecting its mature biomedical research ecosystem, advanced clinical infrastructure, and strong concentration of specialized capabilities for developing complex therapies. The region benefits from established research institutions, experienced clinical investigators, sophisticated manufacturing infrastructure, and regulatory frameworks that support the advancement of innovative therapeutic approaches. Increasing investment in precision medicine and the growing focus on treatments targeting previously difficult-to-manage diseases are expanding clinical development activity. Strong collaboration among researchers, healthcare providers, and therapy developers also facilitates patient recruitment, trial execution, and the translation of emerging technologies into clinical applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by expanding biomedical research capabilities, improving clinical-trial infrastructure, and increasing investment in advanced therapeutic development. Governments and healthcare institutions are strengthening research ecosystems while expanding access to specialized facilities and skilled scientific talent, creating more favorable conditions for cell and gene therapy studies. The region's large and diverse patient populations can also support clinical research across a broad range of disease indications. Growing healthcare expenditure, rising interest in innovative treatments, and increasing regulatory support for advanced therapies are encouraging more clinical development activity. Improvements in specialized manufacturing and trial capabilities are further positioning the region as an increasingly important destination for cell and gene therapy research.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Research StrengthGermany supports the cell and gene therapy clinical trials market through close collaboration between research institutes, hospitals, and biotechnology developers. The country emphasizes high-quality clinical execution and efficient translation of laboratory discoveries into therapeutic studies.
France 🇫🇷
Academic Collaboration NetworkFrance benefits from strong partnerships between clinical research institutions and biotechnology developers in the cell and gene therapy clinical trials market. French trial activity increasingly focuses on expanding access to innovative therapies across specialized treatment centers.
Italy 🇮🇹
Specialized Clinical ExpertiseItaly supports the cell and gene therapy clinical trials market through experienced clinical centers and collaborative research programs. Italian investigators continue expanding expertise in rare diseases and advanced therapies that require highly specialized patient management.
Japan 🇯🇵
Regenerative Medicine PathwayJapan continues to encourage cell and gene therapy clinical trials through its established regenerative medicine ecosystem. Japanese organizations focus on accelerating clinical validation while maintaining rigorous quality standards for advanced therapeutic products.
South Korea 🇰🇷
Clinical Innovation PlatformSouth Korea strengthens the cell and gene therapy clinical trials market by investing in specialized research centers and advanced biomanufacturing capabilities. The country attracts sponsors seeking efficient trial execution supported by modern healthcare infrastructure.
United States 🇺🇸
Advanced Trial EcosystemThe U.S. remains a key location for cell and gene therapy clinical trials due to its extensive research infrastructure and strong collaboration among biotechnology companies, academic institutions, and healthcare providers. Sponsors continue expanding complex trial designs supported by specialized manufacturing capabilities.
Segment Leadership and Growth Trends
Cell and Gene Therapy Clinical Trials Market Share (%), by Phase, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPhase Segment Analysis: Phase III (Largest Segment) vs Phase I (Fastest-Growing Segment)
Phase III trials accounted for a 57.07% share of the cell and gene therapy clinical trials market in 2026, reflecting the substantial concentration of clinical development activity around therapies that have progressed through earlier stages of evaluation. These advanced-stage studies typically require robust clinical evidence to assess therapeutic efficacy and safety across broader patient populations, making them critical to the progression of promising cell and gene therapies toward regulatory submission and commercialization. The increasing focus on translating successful early-stage research into clinically validated treatments supports continued activity in phase III programs, particularly across therapeutic areas with significant unmet medical needs.
Phase I represents the fastest-growing clinical trial phase as developers increasingly advance innovative cell and gene therapies into initial human evaluation. These studies are essential for establishing early safety profiles, determining appropriate treatment approaches, and generating foundational clinical evidence for novel therapeutic candidates. Continued innovation in cellular engineering and gene-based treatment approaches is expanding the pipeline entering first-in-human studies, while growing investment in advanced therapies is supporting broader initiation of early-stage clinical programs.
Indication Segment Analysis: Oncology (Largest Segment) vs Cardiovascular Diseases (Fastest-Growing Segment)
The oncology indication segment held the largest share of the cell and gene therapy clinical trials market in 2026, supported by the extensive development of advanced therapies targeting complex and difficult-to-treat cancers. Cell and gene therapy approaches offer opportunities to address cancer through targeted cellular mechanisms and genetic modification, attracting substantial clinical research interest. The persistent need for innovative treatments, particularly for patients with limited therapeutic options, continues to encourage development activity in oncology. Progress in personalized medicine and increasingly sophisticated therapeutic platforms further strengthens the role of oncology within the clinical trial landscape.
Cardiovascular diseases are the fastest-growing indication as researchers increasingly explore cell and gene therapies for tissue repair, regeneration, and modification of disease-related biological pathways. Cardiovascular conditions can involve significant tissue damage and persistent disease mechanisms, creating opportunities for regenerative and gene-based approaches that extend beyond conventional treatment strategies. Advances in therapeutic delivery, cellular engineering, and regenerative medicine are supporting greater investigation of these approaches, broadening the clinical application of cell and gene therapies beyond their established concentration in oncology.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Phase | Phase I, Phase II, Phase III, Phase IV | Phase III | Phase I |
| Indication | Oncology, Genetic Disorders, Cardiovascular Diseases, Others | Oncology | Cardiovascular Diseases |
Competitive Landscape and Market Positioning
Prominent players in the cell and gene therapy clinical trials market:
1. IQVIA Holdings Inc. (United States)
2. ICON plc (Ireland)
3. Thermo Fisher Scientific Inc. (United States)
4. Laboratory Corporation of America Holdings (United States)
5. Charles River Laboratories International Inc. (United States)
6. Parexel International Corporation (United States)
7. Syneos Health Inc. (United States)
8. Medpace Holdings Inc. (United States)
9. Novotech Health Holdings Pty Ltd. (Australia)
10. Veristat LLC (United States)
The cell and gene therapy clinical trials market is advancing rapidly through intensive research focused on next-generation therapeutic approaches. Collaborative clinical networks are improving trial efficiency and data sharing. Ecosystem integration across research institutions is strengthening innovation pipelines, while new therapy developments are expanding treatment possibilities for complex diseases.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IQVIA Holdings Inc. (United States) | |||||||
| ICON plc (Ireland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Parexel International Corporation (United States) | |||||||
| Syneos Health Inc. (United States) | |||||||
| Medpace Holdings Inc. (United States) | |||||||
| Novotech Health Holdings Pty Ltd. (Australia) | |||||||
| Veristat LLC (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Labcorp | Apr-24 | Labcorp expanded its Precision Oncology portfolio, introducing new molecular residual disease (MRD) platforms and enhanced ctDNA genomic profiling solutions to support biopharmaceutical partners in accelerating drug development and clinical trial programs. |
| IQVIA | Feb-24 | IQVIA established a comprehensive Cell and Gene Therapy Center through strategic alliances with the California Institute for Regenerative Medicine (CIRM), WuXi AppTec, City of Hope, and Charles River Laboratories to streamline the end-to-end development process from preclinical research to commercialization. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cell and Gene Therapy Clinical Trials Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sponsor Type | Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutions, Government & Nonprofit Organizations |
| Therapeutic Modality | Cell Therapy, Gene Therapy, Cell & Gene Combination Therapy |
| Trial Setting | Hospital-Based Trials, Academic Medical Center Trials, Specialized Clinical Research Center Trials, Community-Based Trials |
Cell and Gene Therapy Clinical Trials Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Trial Design & Regulatory Strategy Analysis |
|
| Patient Recruitment & Trial Execution Study |
|
| Manufacturing Readiness Evaluation |
|
Need a different cut of the data?
Request Custom ResearchHow big is the cell and gene therapy clinical trials market?
What is the expected industry size of cell and gene therapy clinical trials by 2036?
How are advances in gene editing and delivery technologies reshaping clinical trial strategies in the cell and gene therapy market?
How are regulatory accelerations and partnerships influencing trial expansion in cell and gene therapy development?
Why is Phase III the largest segment in the cell and gene therapy clinical trials market?
Why is Cardiovascular Diseases the fastest-growing indication in the cell and gene therapy clinical trials market?
Why did North America lead the cell and gene therapy clinical trials market in 2026?
What is driving Asia Pacific’s growth in cell and gene therapy clinical trials?
Who are the major participants shaping the cell and gene therapy clinical trials landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization